Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,396 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Who is the CEO of Integra Lifesciences Holdings Corp?
Ms. Mojdeh Poul is the President of Integra Lifesciences Holdings Corp, joining the firm since 2025.
What is the price performance of IART stock?
The current price of IART is $17.68, it has decreased 10.52% in the last trading day.
What are the primary business themes or industries for Integra Lifesciences Holdings Corp?
Integra Lifesciences Holdings Corp belongs to Health Care industry and the sector is Health Care
What is Integra Lifesciences Holdings Corp market cap?
Integra Lifesciences Holdings Corp's current market cap is $1.3B
Is Integra Lifesciences Holdings Corp a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Integra Lifesciences Holdings Corp, including 2 strong buy, 1 buy, 8 hold, 4 sell, and 2 strong sell